Medication info

Glarinduo Tablet 2.5/500mg

Prescription medicationTabletOralExpired
Ingredient · strength
Linagliptin›2.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Eden Pharma Co., Ltd.
Appearance
Bright yellow, oval-shaped, biconvex film-coated tablet
Packaging
60 tablets/box [(10 tablets/PTP packaging x 6)]
Approval status
Expired

MFDS item code 202001536 · Approved 2020.03.05

This product's status changed to Expired on 2025.03.05. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided the dose is adjusted as follows. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately.

Ingredients

Manufacturer
Eden Pharma Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • difficulty in blood sugar control
View approved original text

This medication is used in conjunction with dietary and exercise therapy to improve blood sugar control in patients with type 2 diabetes in adults. Initially, adequate efficacy can be expected with monotherapy in patients with no prior experience of diabetes drug treatment. If the patient is already on a combination therapy of Linagliptin and Metformin, this medication can be substituted. Additionally, when blood sugar control is difficult with insulin and Metformin combination therapy, this medication can be administered together with insulin. When blood sugar is not controlled with the maximum dose of Metformin and Empagliflozin, blood sugar management can be improved through combination therapy of Empagliflozin and this medication. These various treatment options help provide effective blood sugar management tailored to the individual conditions of each patient.

How to take

Adult dose

The dose of this medication should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of the individual components: linagliptin 2.5 mg and metformin 1000 mg twice daily. This medication is administered twice daily with meals. To reduce gastrointestinal adverse reactions associated with metformin use, the dose should be increased gradually. 1. Patients not currently receiving metformin: For patients with no prior history of antidiabetic drug treatment who do not achieve adequate glycemic control with monotherapy, the initial dose is 1 tablet of this medication 2.5/500 mg twice daily. The dose may be increased to 1 tablet of this medication 2.5/1000 mg twice daily. 2. Switching from combination therapy with linagliptin and metformin: Patients switching from combination therapy with linagliptin and metformin to this medication should take the same doses of linagliptin and metformin that they were previously taking as the initial dose. 3. Patients who do not achieve adequate glycemic control with combination therapy with insulin and metformin: The initial dose of this medication should be considered to provide linagliptin 2.5 mg twice daily (total daily dose 5 mg) and a dose similar to the patient's current metformin dose. When this medication is administered concomitantly with insulin, a reduction in the insulin dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Administer with caution to the following patients). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral hypoglycemic agents to this medication. Any change in treatment for type 2 diabetes may cause a change in glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This medication may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] 45≤~<60 ml/min or estimated glomerular filtration rate (eGFR) 45≤~<60 mL/min/1.73 m2), who do not have other conditions that may increase the risk of lactic acidosis, provided the dose is adjusted as follows. Because the starting dose of metformin is 500mg or 850mg once daily, treatment should not be initiated with this medication. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medication should be discontinued immediately.

Precautions

This medication is primarily used to control blood sugar. One of the ingredients in this medication can cause a serious condition known as lactic acidosis, so individuals with certain health conditions should not take this medication. For example, patients allergic to any of the components of this medication, those with type 1 diabetes, lactic acidosis, diabetic ketoacidosis, severe renal impairment, liver dysfunction, acute alcohol intoxication, pregnant women, and others should not take this medication. Furthermore, this medication should be avoided in cases of sudden deterioration in physical condition or severe heart and lung function decline. This medication can cause hypoglycemia, so care should be taken when used together with other hypoglycemic agents such as insulin or sulfonylureas, and dosages of other medications may need to be adjusted as necessary. Due to the risk of lactic acidosis, any suspicion of dehydration, infection, or renal impairment should be discussed with a physician immediately, and the use of this medication may be temporarily halted. As renal function is critical, regular renal function testing should be conducted before starting this medication and during treatment, and the medication should be discontinued if renal function declines. Special caution is also required for those with heart disease or those undergoing iodine contrast radiography. This medication may need to be discontinued for a certain period before and after surgery or radiological examinations. During treatment with this medication, rare side effects such as acute pancreatitis or bullous pemphigoid may occur, so report any severe abdominal pain or skin abnormalities to a doctor immediately. Prolonged use may lead to vitamin B12 deficiency, so vitamin B12 levels should be checked if symptoms such as anemia or neurological issues arise. This medication can interact with other medications, so it is crucial to inform your doctor or pharmacist if you are taking any other medications. It is advisable to avoid the use of this medication during pregnancy or breastfeeding, and women who plan to become pregnant should also avoid taking this medication. This medication is not recommended for children under the age of 10 or adolescents aged 10 to 17, as its safety and efficacy have not been sufficiently established for this group. Elderly patients may have impaired renal function; hence, renal function should be checked before starting this medication and should be monitored regularly. In case of overdose, lactic acidosis may occur, requiring immediate medical treatment, and in some cases, the medication may need to be removed through hemodialysis. This medication should be kept out of reach of children and should be stored in a sealed container, avoiding moisture and not transferring to another container.

Side effects

  • Pharyngitis
  • hypersensitivity
  • angioedema
  • urticaria
  • lactic acidosis
  • vitamin B12 decrease and deficiency
  • hypoglycemia
  • taste disorder
  • cough
  • decreased appetite
Show 135 more
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer formation
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • blister-like pemphigoid
  • arthralgia with severity and disability
  • rhabdomyolysis
  • increased lipase
  • increased amylase
  • diarrhea
  • hypoglycemia
  • stomatitis
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastroenteritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • speech disorder
  • Alzheimer's dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • anxiety
  • mood disorder
  • insomnia
  • depression
  • bruising
  • bone contusion
  • concussion
  • bone fracture
  • hand fracture
  • laceration
  • palpitations
  • dry eyes
  • cataracts
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • hepatic steatosis
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • kidney transplant failure
  • anemia
  • dizziness
  • sensory loss
  • pruritus
  • hypertension
  • benign prostatic hyperplasia
  • angina
  • acute myocardial infarction
  • unstable angina
  • diarrhea
  • pancreatitis
  • stomatitis
  • mediastinitis
  • pneumonia
  • rhinitis
  • vitreous hemorrhage
  • fever
  • ligament sprain
  • flank pain
  • myelodysplastic syndrome
  • vocal cord polyp
  • dyspepsia
  • anal bleeding
  • cheilitis
  • dental caries
  • enteritis
  • gastritis
  • dizziness
  • headache
  • drowsiness
  • chest discomfort
  • weakness
  • epistaxis
  • oropharyngeal pain
  • voice disorder
  • nasal bleeding
  • altered mental status
  • nocturia
  • dermatitis
  • hyperglycemia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication is sensitive to air and moisture, so it should be stored in a sealed container. It is important to maintain a storage temperature between 1 to 30 degrees Celsius. This will help preserve the efficacy and safety of the medication for a longer period.

Appearance and packaging

Appearance

Bright yellow, oval-shaped, biconvex film-coated tablet

Package unit

60 tablets/box [(10 tablets/PTP packaging x 6)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.